Assisted reproductive technologies and HIV-1 serodiscordant couples

Citation
A. Veiga et al., Assisted reproductive technologies and HIV-1 serodiscordant couples, PRENAT N M, 4(5), 1999, pp. 356-361
Citations number
25
Categorie Soggetti
Reproductive Medicine
Journal title
PRENATAL AND NEONATAL MEDICINE
ISSN journal
13598635 → ACNP
Volume
4
Issue
5
Year of publication
1999
Pages
356 - 361
Database
ISI
SICI code
1359-8635(199910)4:5<356:ARTAHS>2.0.ZU;2-S
Abstract
Objective To describe the results and the safety of assisted reproductive t echniques (artificial insemination and in vitro fertilization with intracyt oplasmic sperm injection (IVF-ICSI)) to assist reproduction in HIV-1 sero-d iscordant couples. Methods The patients were couples asking for assisted reproductive techniqu es because the man was infected with HIV-1. The study period was from Febru ary 1997 to December 1998. Fertility and infectious diseases in men and wom en were evaluated. Sperm was prepared to eliminate HIV-1 viral particles an d a polymerase chain reaction test was performed to exclude the presence of HIV-1. Artificial insemination in stimulated cycles and IVF-ICSI were perf ormed. Results A total of 155 artificial insemination cycles were performed in 64 patients (2.4 cycles per patient, with a. mean number of sperm of 2.4 x 10( 6)). In all 32 pregnancies were achieved (20.6% of the cycles). The pregnan cy rate per couple was 50% (32/64). A good pregnancy rate was observed if t he number of motile inseminated spermatozoa was > 500 000. A total of 16 cy cles of IVF-ICSI were performed in 11 couples; four pregnancies were achiev ed. The pregnancy rates per replacement and per patient were 26.6% and 36.4 %, respectively. The implantation rate was 18.1%. No infection among women or newborns was observed following artificial insemination or IVF-ICSI. Conclusion Although female partner infection cannot completely be ruled out , artificial insemination and IVF-ICSI after sperm preparation appear to be safe techniques in sero-discordant couples for HIV-1.